194 related articles for article (PubMed ID: 16420255)
1. Minor changes in calculated creatinine clearance and anion-gap are associated with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy.
Winston A; Amin J; Mallon P; Marriott D; Carr A; Cooper DA; Emery S
HIV Med; 2006 Mar; 7(2):105-11. PubMed ID: 16420255
[TBL] [Abstract][Full Text] [Related]
2. Temporal changes in renal glomerular function associated with the use of Tenofovir Disoproxil Fumarate in HIV-infected Nigerians.
Agbaji OO; Agaba PA; Idoko JA; Taiwo B; Murphy R; Kanki P; Ekong E
West Afr J Med; 2011; 30(3):164-8. PubMed ID: 22120479
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of hypophosphataemia in tenofovir disoproxil fumarate (TDF)-exposed and TDF-unexposed HIV-infected out-patients receiving highly active antiretroviral therapy.
Buchacz K; Brooks JT; Tong T; Moorman AC; Baker RK; Holmberg SD; Greenberg A;
HIV Med; 2006 Oct; 7(7):451-6. PubMed ID: 16925731
[TBL] [Abstract][Full Text] [Related]
4. Renal function in antiretroviral-experienced patients treated with tenofovir disoproxil fumarate associated with atazanavir/ritonavir.
Gérard L; Chazallon C; Taburet AM; Girard PM; Aboulker JP; Piketty C
Antivir Ther; 2007; 12(1):31-9. PubMed ID: 17503745
[TBL] [Abstract][Full Text] [Related]
5. Antiviral efficacy and genotypic resistance patterns of combination therapy with stavudine/tenofovir in highly active antiretroviral therapy experienced patients.
Antinori A; Trotta MP; Nasta P; Bini T; Bonora S; Castagna A; Zaccarelli M; Quirino T; Landonio S; Merli S; Tozzi V; Di Perri G; Andreoni M; Perno CF; Carosi G
Antivir Ther; 2006; 11(2):233-43. PubMed ID: 16640104
[TBL] [Abstract][Full Text] [Related]
6. Tenofovir use is associated with a reduction in calculated glomerular filtration rates in the Swiss HIV Cohort Study.
Fux CA; Simcock M; Wolbers M; Bucher HC; Hirschel B; Opravil M; Vernazza P; Cavassini M; Bernasconi E; Elzi L; Furrer H;
Antivir Ther; 2007; 12(8):1165-73. PubMed ID: 18240857
[TBL] [Abstract][Full Text] [Related]
7. Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study.
Izzedine H; Hulot JS; Vittecoq D; Gallant JE; Staszewski S; Launay-Vacher V; Cheng A; Deray G;
Nephrol Dial Transplant; 2005 Apr; 20(4):743-6. PubMed ID: 15741212
[TBL] [Abstract][Full Text] [Related]
8. Exploring mitochondrial nephrotoxicity as a potential mechanism of kidney dysfunction among HIV-infected patients on highly active antiretroviral therapy.
Côté HC; Magil AB; Harris M; Scarth BJ; Gadawski I; Wang N; Yu E; Yip B; Zalunardo N; Werb R; Hogg R; Harrigan PR; Montaner JS
Antivir Ther; 2006; 11(1):79-86. PubMed ID: 16518963
[TBL] [Abstract][Full Text] [Related]
9. Factors associated with the emergence of K65R in patients with HIV-1 infection treated with combination antiretroviral therapy containing tenofovir.
von Wyl V; Yerly S; Böni J; Bürgisser P; Klimkait T; Battegay M; Bernasconi E; Cavassini M; Furrer H; Hirschel B; Vernazza PL; Rickenbach M; Ledergerber B; Günthard HF;
Clin Infect Dis; 2008 Apr; 46(8):1299-309. PubMed ID: 18444871
[TBL] [Abstract][Full Text] [Related]
10. Genotypic determinants of the virological response to tenofovir disoproxil fumarate in nucleoside reverse transcriptase inhibitor-experienced patients.
Masquelier B; Tamalet C; Montès B; Descamps D; Peytavin G; Bocket L; Wirden M; Izopet J; Schneider V; Ferré V; Ruffault A; Palmer P; Trylesinski A; Miller M; Brun-Vézinet F; Costagliola D;
Antivir Ther; 2004 Jun; 9(3):315-23. PubMed ID: 15259894
[TBL] [Abstract][Full Text] [Related]
11. Antiretroviral efficacy and virological profile of a zidovudine/lamivudine/tenofovir disoproxil fumarate combination therapy in antiretroviral-naive patients.
Masquelier B; Neau D; Boucher S; Lavignolle-Aurillac V; Schrive MH; Recordon-Pinson P; Ragnaud JM; Fleury H
Antivir Ther; 2006; 11(6):827-30. PubMed ID: 17310827
[TBL] [Abstract][Full Text] [Related]
12. Incidence of and risk factors for tenofovir-induced nephrotoxicity: a retrospective cohort study.
Antoniou T; Raboud J; Chirhin S; Yoong D; Govan V; Gough K; Rachlis A; Loutfy M
HIV Med; 2005 Jul; 6(4):284-90. PubMed ID: 16011534
[TBL] [Abstract][Full Text] [Related]
13. Observational study on HIV-infected subjects failing HAART receiving tenofovir plus didanosine as NRTI backbone.
Bongiovanni M; Gianotti N; Chiesa E; Nasta P; Cicconi P; Capetti A; di Biagio A; Matti A; Tirelli V; Marconi P; de Luca A; Mussini C; Gatti F; Zaccarelli M; Abeli C; Torti C; Antinori A; Castagna A; d'Arminio Monforte A
Infection; 2007 Dec; 35(6):451-6. PubMed ID: 18034204
[TBL] [Abstract][Full Text] [Related]
14. Salvage therapy with atazanavir/ritonavir combined to tenofovir in HIV-infected patients with multiple treatment failures: randomized ANRS 107 trial.
Piketty C; Gérard L; Chazallon C; Marcelin AG; Clavel F; Taburet AM; Calvez V; Madelaine-Chambrin I; Molina JM; Aboulker JP; Girard PM;
Antivir Ther; 2006; 11(2):213-21. PubMed ID: 16640102
[TBL] [Abstract][Full Text] [Related]
15. Clinical and genotypic correlates of mutation K65R in HIV-infected patients failing regimens not including tenofovir.
Trotta MP; Bonfigli S; Ceccherini-Silberstein F; Bellagamba R; D'Arrigo R; Soldani F; Zaccarelli M; Concetta Bellocchi M; Lorenzini P; Marconi P; Boumis E; Forbici F; Comandini UV; Tozzi V; Narciso P; Federico Perno C; Antinori A
J Med Virol; 2006 May; 78(5):535-41. PubMed ID: 16555278
[TBL] [Abstract][Full Text] [Related]
16. In utero exposure to tenofovir disoproxil fumarate does not impair growth and bone health in HIV-uninfected children born to HIV-infected mothers.
Viganò A; Mora S; Giacomet V; Stucchi S; Manfredini V; Gabiano C; Salvini F; Cellini M; Tamburrini E; Puzzovio M; Zuccotti GV
Antivir Ther; 2011; 16(8):1259-66. PubMed ID: 22155907
[TBL] [Abstract][Full Text] [Related]
17. Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment.
Gallant JE; Parish MA; Keruly JC; Moore RD
Clin Infect Dis; 2005 Apr; 40(8):1194-8. PubMed ID: 15791522
[TBL] [Abstract][Full Text] [Related]
18. The effect of tenofovir disoproxil fumarate on whole-body insulin sensitivity, lipids and adipokines in healthy volunteers.
Randell PA; Jackson AG; Zhong L; Yale K; Moyle GJ
Antivir Ther; 2010; 15(2):227-33. PubMed ID: 20386078
[TBL] [Abstract][Full Text] [Related]
19. Reduced glomerular filtration rate but sustained virologic response in HIV/hepatitis B co-infected individuals on long-term tenofovir.
Tan LK; Gilleece Y; Mandalia S; Murungi A; Grover D; Fisher M; Atkins M; Nelson M
J Viral Hepat; 2009 Jul; 16(7):471-8. PubMed ID: 19457140
[TBL] [Abstract][Full Text] [Related]
20. Tenofovir disoproxil fumarate-emtricitabine coformulation for once-daily dual NRTI backbone.
Muñoz de Benito RM; Arribas López JR
Expert Rev Anti Infect Ther; 2006 Aug; 4(4):523-35. PubMed ID: 17009933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
